Ryeqo

News

Around 1,000 women in England a year with endometriosis will soon have access to the first daily oral therapy, Gedeon Richter's Ryeqo, via the NHS.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.